SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and a sharp multi-year price decline following a weak outlook and concerns over declining demand in China. While the community remains deeply divided, with some investors betting on a generational value play due to the brand's iconic status and dividend, others are aggressively shorting the stock, citing poor leadership, brand dilution, and concerns that the company's growth model is fundamentally broken.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heightened volatility and intense social media debate as investors react to the company's pause in Bitcoin accumulation and ongoing concerns regarding stock dilution. The community remains deeply polarized, with bulls pointing to the company's long-term Bitcoin treasury strategy while vocal critics argue that the reliance on equity offerings to fund operations creates an unsustainable path for shareholders.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny and bearish sentiment from investors concerned about a lack of clear communication regarding the company's Helios data center progress and perceived mismanagement. Despite interest from institutional research desks, the stock is currently struggling with high volatility and underperformance, leading many in the community to express frustration over the silence from leadership during recent market fluctuations.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a surprise leadership overhaul that replaced CEO Peter Greenleaf with board chair Kevin Tang, a move widely interpreted by the community as a strategic catalyst for an accelerated company sale. Shareholders are actively debating whether Tangs decision to forgo compensation and his recent heavy accumulation of shares signals an imminent buyout or a shift toward aggressive value maximization.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility following a mixed quarterly report where revenue beat analyst estimates while earnings fell short of expectations. The community remains deeply divided, with bulls pointing to the company's long-term luxury ecosystem strategy and potential tariff relief as major catalysts, while bears warn of ongoing debt pressures, weakening housing trends, and a business model struggling to sustain high-end demand.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is surging following the announcement of a clinical development collaboration with Pfizer for its multiple myeloma candidate, alongside a private placement financing deal. The community is actively debating the stock's massive upside potential driven by this institutional endorsement and high short interest, while some traders caution against volatility as they watch for sustained volume to fuel a potential squeeze.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing high volatility as investors track its history as a parabolic runner, leading to intense debate over whether it is primed for another short squeeze or remains a high-risk pump-and-dump scheme. Community discussion is heavily focused on the stock's low float, rising cost-to-borrow fees, and speculation regarding potential retail-driven "meme" momentum compared to its past price spikes.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining significant community attention as a new, pure-play vehicle offering direct exposure to SpaceX and other space exploration companies ahead of anticipated industry milestones. Investors are actively debating the fund's early AUM and liquidity, drawing frequent comparisons to other space-themed ETFs and speculating on potential price momentum as interest in commercial space activity intensifies.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop has experienced a sharp pullback from its previous highs, prompting a heated debate among investors regarding whether the stock is a long-term bargain or a fundamentally overvalued name heading for further downside. While some traders are actively buying the dip on hopes of future global expansion and share buybacks, others are shorting the stock, pointing to concerns over consumer fatigue and high valuation metrics relative to its restaurant peers.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is experiencing heightened investor interest and speculative momentum following the announcement of a multi-year AI cloud infrastructure contract. The community is actively discussing the company's low-float structure and potential for a short squeeze, with many users weighing the risks of volatility and lack of volume against the company's long-term enterprise pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Acme United (ACU) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Consumer Discretionary Stocks Lagging  Acme United (ACU) This Year?

Here is how Acme United Corporation. (ACU) and Carter's (CRI) have performed compared to their sector so far this year.

Strength Seen in Acme United (ACU): Can Its 5.0% Jump Turn into More Strength?

Acme United (ACU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Acme United Corporation. (ACU) Q4 Earnings Meet Estimates

Acme United (ACU) delivered earnings and revenue surprises of 0.00% and -1.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Acme United Corp. is engaged in the supply of cutting devices, measuring instruments, and safety products for school, home, office, hardware and industrial use. The firm offers its products under the brands Camillus, Clauss, Cuda, DMT Sharpeners, First Aid Only, Med-Nap, Pac-Kit, Physicianscare, Spill Magic, Westcott, Western, and First Aid Central. It operates through the following geographical segments: United States, Canada, and Europe. The company was founded in 1867 and is headquartered in Shelton, CT.

Acme United Corp.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$44.64
Prev Close	$44.91
Open	$45.06
Dividend Yield	1.56%
50-Day Moving Average	$43.81
Beta	0.66
Avg. Volume	9,625.61
PE Ratio	18.10

52-Week High	$47.31
52-Week Low	$35.31
Market Capitalization	$171.03M
EPS (Annual)	$2.49
Price to Book	1.45
Revenue Per Employee	$302,837.93

ACU
Acme United Corp.

Feed

News

Sentiment

Fundamentals

Info

Latest ACU News

ACUAcme United Corp.